| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 5, 2026 | ±2.3% | -1.9% | over-priced |
| October 28, 2025 | ±1.9% | +0.5% | over-priced |
| August 11, 2025 | ±3.3% | +0.6% | over-priced |
| May 7, 2025 | ±2.9% | -0.9% | over-priced |
| November 4, 2024 | ±1.3% | -1.7% | under-priced |
| August 9, 2024 | ±2.8% | -1.3% | over-priced |
| May 9, 2024 | ±1.4% | +0.8% | over-priced |
| November 6, 2023 | ±1.6% | +0.5% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $6.90 | $111.7B | $6.5B |
| Q4 FY2025 | $0.02 | $113.2B | $218M |
| Q3 FY2025 | $2.59 | $113.2B | $2.5B |
| Q2 FY2025 | $3.74 | $111.6B | $3.6B |
UNITEDHEALTH GROUP INCORPORATED (Delaware) (UNH) reports in 97 days, with the next report estimated for September 18, 2026. Across the last 8 reports, options priced an average ±2.2% earnings move while the stock actually moved 1.0% on average — the market has systematically over-priced UNH's earnings risk. Fundamentals into the print: EPS up 0.7% year-over-year, revenue up 2.0%. QuantLogix's live 5-factor engine currently reads UNH as a buy at 64/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →